Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Fusen Pharmaceutical Company Limited
福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT
"GLUCOSAMINE SULFATE CAPSULE" APPROVED FOR MARKETING

The board of directors (the "**Board**") of Fusen Pharmaceutical Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that "Glucosamine Sulfate Capsule" (trademark: Shuhuitong* 舒匯通) developed by Henan Fusen Pharmaceutical Company Limited, a wholly-owned subsidiary of the Company, has obtained the approval for marketing from the National Medical Products Administration of the PRC for the treatment of primary and secondary osteoarthritis.

Glucosamine Sulfate Capsule tablets consist of natural amino monosaccharides, which is an essential substance for the synthesis of human articular cartilage matrix. As a protective agent for articular cartilages, it can alleviate joint pain and improve joint functions, repair cartilage, strengthen joints, and facilitate the repair and reconstruction of cartilage matrix, thereby delaying the pathological process and development of osteoarthritis, thus improving joint mobility and alleviating pain. Osteoarthritis is a degenerative disease associated with age, body weight, joint strain and other factors, with a chronic duration and a tendency to recur. Patients not only require short-term pain relief, but also long-term maintenance of joint function. Glucosamine Sulfate Capsules precisely meet this therapeutic need.

Glucosamine Sulfate Capsule is a Class B drug under the "National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2025 Edition)". According to data from Menet, the sales revenue of Glucosamine Sulfate Capsules exceeded RMB850 million in 2024, with year-on-year growth of 25.28% for the full year of 2024 and 26.84% for the first three quarters of 2025.

With the intensifying aging of the domestic population, the prevalence of joint diseases and osteoarthritis continues to rise, and shows a trend of affecting younger generations. The demand for treatment of osteoarticular diseases is exhibiting a long-term growth trend. As a typical drug that combines both therapeutic and healthcare functions, the market potential and clinical value of Glucosamine Sulfate Capsule are expected to be further unleashed alongside the in-depth implementation of the Healthy China Strategy during the "15th Five-Year Plan" period and the enhancement of public health management awareness.

Glucosamine Sulfate Capsule is another important product of the Group, which further enriches the Company's product pipeline. The approval of this product marks a solid step forward for Fusen Pharmaceutical in the therapeutic area of osteoarthritis and will provide more therapeutic options for patients suffering from osteoarthritis.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

Hong Kong, 17 April 2026

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.

* *for identification purpose only*